Related Experiment Videos
Tacrine efficacy in Lewy body dementia
F Lebert1, F Pasquier, L Souliez
1Memory Clinic, Centre Hospitalier Universitaire and Faculté de Médecine, Lille, France. fllebert@minitel.net
International Journal of Geriatric Psychiatry
|September 11, 1998
Summary
Tacrine response varied between Alzheimer's disease (AD) and Lewy body dementia (LBD) patients. Cognitive improvements differed, highlighting the need for tailored assessments in dementia treatment.
Area of Science:
- Neurology
- Pharmacology
- Cognitive Science
Background:
- Patient response to tacrine, a dementia medication, is inconsistent in Alzheimer's disease (AD).
- Lewy body dementia (LBD) is hypothesized as a potential subtype of AD with a heightened response to tacrine.
- Understanding differential drug responses is crucial for effective dementia management.
Purpose of the Study:
- To investigate and compare the efficacy of tacrine in patients with Alzheimer's disease (AD) versus Lewy body dementia (LBD).
- To identify specific cognitive domains affected by tacrine in each patient group.
Main Methods:
- A cohort of 75 patients with mild to moderate AD were screened.
- Tacrine was administered in a dose-escalation regimen (40, 80, and 120 mg/day) over 12 weeks.
- Cognitive performance was assessed at baseline and during treatment with 120 mg/day tacrine.
Main Results:
- Out of 39 analyzed patients (20 AD, 19 LBD), 22 showed cognitive improvement with tacrine.
- Alzheimer's disease patients experienced improvements in conceptualization.
- Lewy body dementia patients demonstrated enhanced verbal initiation and digit span performance.
Conclusions:
- Tacrine's therapeutic effects vary significantly between AD and LBD patient groups.
- Differential cognitive improvements suggest distinct underlying pathologies or drug interactions.
- The study underscores the necessity of employing precise cognitive tests to accurately evaluate pharmacological interventions in dementia.